Pfizer, AbCellera in Multi-Target Research Pact

AbCellera Biologics, Inc. has entered a new therapeutic antibody discovery collaboration with Pfizer to apply its monoclonal antibody (mAb) screening platform to discover function-modulating antibodies against undisclosed membrane protein targets. 
 
AbCellera will receive an upfront payment and research support, and will be eligible to receive as much as $90 million in milestones, and royalties based on Pfizer’s development and commercialization of antibodies generated under this collaboration.
 
Carl Hansen, founding chief executive officer of AbCellera, said, "We are increasingly recognized as a leader in high-performance antibody discovery. Our platform allows us to screen natural immune repertoires with unparalleled depth to unlock the most challenging discovery programs. We welcome the opportunity to work closely with the innovative team at Pfizer and look forward to building a lasting relationship."
 
"We are pleased to work with the team at AbCellera using their innovative antibody discovery platform," said Will Somers, vice president of Biomedicines Design, Pfizer. "We hope this platform can aid in our research as we look to bring novel medicines to patients, seeking to discover modulators of a transmembrane protein in a therapeutically important target class."